Trial · NCT02564900
Adverse events3,094
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 3,094
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nasopharyngitis | Infections and infestations | Dose Escalation: Cohort 1, 0.8 mg/kg | 1 | 3 | |
| other | Nasopharyngitis | Infections and infestations | Dose Escalation: Cohort 2, 1.6 mg/kg | 1 | 3 | |
| other | Nasopharyngitis | Infections and infestations | Dose Escalation: Cohort 3, 3.2 mg/kg | 0 | 3 | |
| other | Nasopharyngitis | Infections and infestations | Dose Escalation: Cohort 4, 5.4 mg/kg | 2 | 6 | |
| other | Nasopharyngitis | Infections and infestations | Dose Escalation: Cohort 5, 6.4 mg/kg | 0 | 6 | |
| other | Nasopharyngitis | Infections and infestations | Dose Escalation: Cohort 6, 8.0 mg/kg | 0 | 6 | |
| other | Nasopharyngitis | Infections and infestations | Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg | 5 | 50 | |
| other | Nasopharyngitis | Infections and infestations | Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg | 9 | 66 | |
| other | Nasopharyngitis | Infections and infestations | Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg | 0 | 21 | |
| other | Nasopharyngitis | Infections and infestations | Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg | 4 | 33 | |
| other | Nasopharyngitis | Infections and infestations | Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg | 0 | 19 | |
| other | Nasopharyngitis | Infections and infestations | Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg | 3 | 25 | |
| other | Nasopharyngitis | Infections and infestations | Dose Expansion: HER2-expressing Other Solid Tumors | 6 | 59 | |
| other | Upper respiratory tract infection | Infections and infestations | Dose Escalation: Cohort 1, 0.8 mg/kg | 0 | 3 | |
| other | Upper respiratory tract infection | Infections and infestations | Dose Escalation: Cohort 2, 1.6 mg/kg | 0 | 3 | |
| other | Upper respiratory tract infection | Infections and infestations | Dose Escalation: Cohort 3, 3.2 mg/kg | 1 | 3 | |
| other | Upper respiratory tract infection | Infections and infestations | Dose Escalation: Cohort 4, 5.4 mg/kg | 2 | 6 | |
| other | Upper respiratory tract infection | Infections and infestations | Dose Escalation: Cohort 5, 6.4 mg/kg | 0 | 6 | |
| other | Upper respiratory tract infection | Infections and infestations | Dose Escalation: Cohort 6, 8.0 mg/kg | 0 | 6 | |
| other | Upper respiratory tract infection | Infections and infestations | Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg | 9 | 50 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02564900/events